CrownBio, a specialist in the field of preclinical immuno-oncology research, offers a chimeric antigen receptor T-cell platform for proof-of-concept and therapeutic efficacy validation
The company has enhanced its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities.
The addition of bioluminescence imaging for non-invasive evaluation of systemic and orthotopic tumour progression, in real-time, further enhances an already robust platform and provides a unique set of solutions to advance CAR T-cell therapies.
Crown Bioscience is a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research.
CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics. CAR T-cell agents utilise CAR T-cells that recognise tumor-associated antigens and subsequently promote tumour elimination.
The remarkable efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Clinically relevant in vivo and in vitro models combine with a comprehensive suite of analytical services to enable efficient, early evaluation of CAR T-cell agents.
"We are committed to delivering innovative services to help our clients' develop improved cancer therapeutics," said Dr Rajendra Kumari, CrownBio's Chief Scientific Officer, UK.
"Our non-invasive bioluminescent imaging capabilities, applied to CAR T-cell evaluation platform, deliver cutting-edge in vivo data that helps drug developers uncover insights to guide successful downstream development and clinical application of CAR T-cell agents."